China is there own complete regulatory process, a share I previously owned was going down the CFDA pathway but it has taken an extremely long time due to China only recognising tests done in China for the process.
Not sure if it would be the same for RAP
Ann: ResAppDx-EU for Adult Respiratory Disease Receives CE Mark, page-41
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 100 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)